Compounds > niacinamide
Page last updated: 2024-10-19

niacinamide and Venous Thrombosis

niacinamide has been researched along with Venous Thrombosis in 35 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Venous Thrombosis: The formation or presence of a blood clot (THROMBUS) within a vein.

Research Excerpts

ExcerptRelevanceReference
"The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma."9.24Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. ( Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J, 2017)
"To evaluate the safety and efficacy of combined endovascular brachytherapy (EVBT), transarterial chemoembolization (TACE), and sorafenib to treat hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (MPVTT)."9.24Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. ( Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH, 2017)
"This phase 2 study evaluated the efficacy of radiation therapy (RT) with concurrent and sequential sorafenib therapy in patients with unresectable hepatocellular carcinoma (HCC)."9.19Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. ( Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC, 2014)
"To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT)."9.19Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. ( Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K, 2014)
"We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting."9.17Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. ( Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY, 2013)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."7.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
"Sorafenib has been a standard therapy for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis."7.81[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report]. ( Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T, 2015)
"To compare efficacy of transarterial chemoembolization with and without radiation therapy (RT) versus sorafenib for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."7.81Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. ( Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM, 2015)
"Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)."7.81Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015)
"We report the first case of initially unresectable advanced hepatocellular carcinoma (HCC) with portal vein and hepatic venous tumor thrombosis and multiple lung metastases that allowed for curative hepatectomy after multidisciplinary treatment including sorafenib."7.81Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. ( Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S, 2015)
"To investigate the efficacy of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis."7.80[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis]. ( Chen, J; Chen, S; Wu, B; Xi, W; Yu, H, 2014)
"The most common AEs were hand-foot skin reaction related to sorafenib and fever related to TACE."7.80Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. ( Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M, 2014)
"Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients."7.79Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. ( Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M, 2013)
"We report two cases of locally advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) who complete regression by sorafenib treatment allowed curative resection."7.77Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. ( Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M, 2011)
"We evaluated the effect of sorafenib and intermittent hepatic arterial infusion chemotherapy (HAIC) using cisplatin for unresectable advanced hepatocellular carcinoma (HCC)."7.76[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y, 2010)
"Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial."5.43Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. ( Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY, 2016)
"Patients with advanced hepatocellular carcinoma (HCC) showing portal vein tumor thrombosis (PVTT) have an extremely poor prognosis."5.43Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. ( Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M, 2016)
"To evaluate the safety and efficacy of combined endovascular brachytherapy (EVBT), transarterial chemoembolization (TACE), and sorafenib to treat hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (MPVTT)."5.24Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. ( Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH, 2017)
"The purpose of this study was to examine the safety and efficacy of sorafenib in Chinese patients with unresectable hepatocellular carcinoma."5.24Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. ( Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J, 2017)
"This phase 2 study evaluated the efficacy of radiation therapy (RT) with concurrent and sequential sorafenib therapy in patients with unresectable hepatocellular carcinoma (HCC)."5.19Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. ( Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC, 2014)
"To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT)."5.19Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. ( Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K, 2014)
"We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting."5.17Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. ( Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY, 2013)
"To evaluate the efficacy of transcatheter arterial chemoembolisation (TACE) compared with surgical intervention and sorafenib for treatment of hepatocellular carcinoma (HCC) in patients with tumor thrombus extending to the main portal vein."3.83Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. ( Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ, 2016)
"We report the first case of initially unresectable advanced hepatocellular carcinoma (HCC) with portal vein and hepatic venous tumor thrombosis and multiple lung metastases that allowed for curative hepatectomy after multidisciplinary treatment including sorafenib."3.81Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. ( Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S, 2015)
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)."3.81A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015)
"Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)."3.81Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015)
"To compare efficacy of transarterial chemoembolization with and without radiation therapy (RT) versus sorafenib for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)."3.81Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. ( Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM, 2015)
"Sorafenib has been a standard therapy for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis."3.81[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report]. ( Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T, 2015)
"The most common AEs were hand-foot skin reaction related to sorafenib and fever related to TACE."3.80Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. ( Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M, 2014)
"To investigate the efficacy of transcatheter arterial chemoembolization (TACE) plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis."3.80[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis]. ( Chen, J; Chen, S; Wu, B; Xi, W; Yu, H, 2014)
"Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients."3.79Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib. ( Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M, 2013)
" She was diagnosed with unresectable hepatocellular carcinoma (HCC) with PVTT, and sorafenib in combination with intermittent cisplatin(CDDP) hepatic arterial infusion chemotherapy(HAIC)was performed."3.78[A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T, 2012)
"We report two cases of locally advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) who complete regression by sorafenib treatment allowed curative resection."3.77Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. ( Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M, 2011)
"We evaluated the effect of sorafenib and intermittent hepatic arterial infusion chemotherapy (HAIC) using cisplatin for unresectable advanced hepatocellular carcinoma (HCC)."3.76[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study]. ( Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y, 2010)
" Frequently occurring motesanib-related adverse events included diarrhea (n = 19), nausea (n = 18), vomiting (n = 13), and fatigue (n = 12), which were mostly of worst grade < 3."2.76Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. ( Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S, 2011)
"According to the Barcelona Clinic Liver Cancer (BCLC) Staging System (which is the most widely adopted HCC management guideline), sorafenib is the standard of care for advanced HCC (i."2.53Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. ( Gwon, DI; Han, K; Kim, JH; Ko, GY; Sung, KB, 2016)
"Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging."2.52New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. ( Heo, J; Woo, HY, 2015)
"Management of hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) is complex and requires an understanding of multiple therapeutic options."2.52Management of hepatocellular carcinoma with portal vein thrombosis. ( Kim, YH; Lee, EW; Quirk, M; Saab, S, 2015)
"The optimal treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) remains controversial."1.43Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. ( Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ, 2016)
"Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial."1.43Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. ( Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY, 2016)
"Patients with advanced hepatocellular carcinoma (HCC) showing portal vein tumor thrombosis (PVTT) have an extremely poor prognosis."1.43Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. ( Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M, 2016)
" The radioembolization group also experienced fewer severe adverse effects."1.43Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. ( Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M, 2016)
"Ten percent of patients with kidney cancer have associated vena cava thrombus, which is associated with a high operative morbidity."1.35[Regression of vena cava tumour thrombus in response to sorafenib]. ( Bart, S; Billemont, B; Bitker, MO; Izzedine, H; Rixe, O; Sultan, V; Thibault, F, 2008)
"MNA, however, did not affect venous thrombosis."1.341-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. ( Adamus, J; Bartus, M; Buczko, W; Chlopicki, S; Gebicki, J; Lomnicka, M; Mogielnicki, A; Swies, J, 2007)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (8.57)29.6817
2010's32 (91.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ye, SL1
Chen, X1
Yang, J1
Bie, P1
Zhang, S1
Liu, F1
Liu, L1
Zhou, J1
Dou, K1
Yip, CS1
Yang, X1
Zhang, H1
Zhang, ZH1
Liu, QX1
Zhang, W1
Ma, JQ1
Wang, JH1
Luo, JJ1
Liu, LX1
Yan, ZP1
Kermiche-Rahali, S1
Di Fiore, A1
Drieux, F1
Di Fiore, F1
François, A1
Scotté, M1
Jeong, SW1
Jang, JY2
Shim, KY1
Lee, SH2
Kim, SG1
Cha, SW1
Kim, YS2
Cho, YD1
Kim, HS1
Kim, BS2
Kim, KH1
Kim, JH3
Chen, SW1
Lin, LC1
Kuo, YC1
Liang, JA1
Kuo, CC1
Chiou, JF1
Kwon, T1
Lee, JL1
You, D1
Jeong, IG1
Song, C1
Ahn, H1
Kim, CS1
Hong, JH1
Zhu, K1
Chen, J3
Lai, L1
Meng, X1
Zhou, B1
Huang, W1
Cai, M1
Shan, H1
Nakazawa, T1
Hidaka, H1
Shibuya, A1
Okuwaki, Y1
Tanaka, Y1
Takada, J1
Minamino, T1
Watanabe, M1
Kokubu, S1
Koizumi, W1
Song, DS1
Song, MJ1
Bae, SH2
Chung, WJ2
Park, JY1
Yim, HJ1
Cho, SB1
Park, SY2
Yang, JM1
Pan, T1
Li, XS1
Xie, QK1
Wang, JP1
Li, W1
Wu, PH1
Zhao, M1
Edeline, J2
Crouzet, L2
Le Sourd, S1
Larible, C1
Brunot, A1
Le Roy, F1
Cattenoz, C1
Latournerie, M1
Gédouin, D1
Guillygomarc'h, A2
Boucher, E3
Xi, W1
Wu, B1
Yu, H1
Chen, S1
Kim, GA1
Shim, JH1
Yoon, SM1
Jung, J1
Ryu, MH1
Ryoo, BY1
Kang, YK1
Lee, D1
Kim, KM1
Lim, YS1
Lee, HC1
Chung, YH1
Lee, YS1
Quirk, M1
Kim, YH3
Saab, S1
Lee, EW1
Woo, HY1
Heo, J2
Kitajima, T1
Hatano, E1
Mitsunori, Y1
Taura, K1
Fujimoto, Y1
Mizumoto, M1
Okajima, H1
Kaido, T1
Minamiguchi, S1
Uemoto, S1
Campillo-Gimenez, B1
Rolland, Y1
Pracht, M2
Boudjema, K1
Lenoir, L1
Adhoute, X1
Rohou, T1
Clément, B1
Blanc, JF1
Garin, E1
Han, K1
Ko, GY1
Gwon, DI1
Sung, KB1
Tsukamoto, T1
Kanazawa, A1
Shimizu, S1
Murata, A1
Sakae, M1
Kurihara, S1
Tashima, T1
Deguchi, S1
Nakai, T1
Kawasaki, Y1
Kioka, K1
Wang, K1
Guo, WX1
Chen, MS1
Mao, YL1
Sun, BC1
Shi, J1
Zhang, YJ1
Meng, Y1
Yang, YF1
Cong, WM1
Wu, MC1
Lau, WY1
Cheng, SQ1
Lee, JM1
Jang, BK1
Lee, YJ1
Choi, WY1
Choi, SM1
Hwang, JS1
Kang, KJ1
Chauhan, AK1
Tak, WY1
Kweon, YO1
Lee, CH1
Ye, HH1
Ye, JZ1
Xie, ZB1
Peng, YC1
Ma, L1
Bai, T1
Chen, JZ1
Lu, Z1
Qin, HG1
Xiang, BD1
Li, LQ1
Cho, YY1
Lee, M1
Kim, HC1
Chung, JW1
Gwak, GY1
Kim, do Y1
Kim, YJ1
Gorodetski, B1
Chapiro, J1
Schernthaner, R1
Duran, R1
Lin, M1
Lee, H1
Lenis, D1
Stuart, EA1
Nonyane, BA1
Pekurovsky, V1
Tamrazi, A1
Gebauer, B1
Schlachter, T1
Pawlik, TM1
Geschwind, JF1
Takano, M1
Kokudo, T1
Miyazaki, Y1
Kageyama, Y1
Takahashi, A1
Amikura, K1
Sakamoto, H1
Wu, SS1
Yen, HH1
Chung, CY1
Thibault, F1
Izzedine, H1
Sultan, V1
Bart, S1
Billemont, B1
Rixe, O1
Bitker, MO1
Leroux, C1
Vauléon, E1
Zoheir, Y1
Audrain, O1
Raoul, JL1
Ishizaki, M2
Kaibori, M2
Matsui, K2
Yanagimoto, Y1
Nakatake, R2
Kwon, AH2
Irtan, S1
Chopin-Laly, X1
Ronot, M1
Faivre, S1
Paradis, V1
Belghiti, J1
Kotasek, D1
Tebbutt, N1
Desai, J1
Welch, S1
Siu, LL1
McCoy, S1
Sun, YN1
Johnson, J1
Adewoye, AH1
Price, T1
Takeda, H1
Nakano, Y1
Kashiwagi, Y1
Yoshino, Y1
Gotoh, M1
Matsushima, H1
Sakaguchi, T1
Chlopicki, S1
Swies, J1
Mogielnicki, A1
Buczko, W1
Bartus, M1
Lomnicka, M1
Adamus, J1
Gebicki, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949]Phase 1/Phase 239 participants (Anticipated)Interventional2019-12-01Not yet recruiting
Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587]Early Phase 160 participants (Anticipated)Interventional2021-07-01Enrolling by invitation
A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors[NCT01235416]Phase 157 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for niacinamide and Venous Thrombosis

ArticleYear
Management of hepatocellular carcinoma with portal vein thrombosis.
    World journal of gastroenterology, 2015, Mar-28, Volume: 21, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contraindications;

2015
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:2

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver

2015
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
    World journal of gastroenterology, 2016, Jan-07, Volume: 22, Issue:1

    Topics: ADAM17 Protein; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy

2016

Trials

6 trials available for niacinamide and Venous Thrombosis

ArticleYear
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Hepatocellular; China; Disease-Free Surviva

2017
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
    World journal of gastroenterology, 2017, Nov-21, Volume: 23, Issue:43

    Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Com

2017
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Gut and liver, 2013, Volume: 7, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea

2013
Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
    International journal of radiation oncology, biology, physics, 2014, Apr-01, Volume: 88, Issue:5

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Drug Adm

2014
Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
    Radiology, 2014, Volume: 272, Issue:1

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Female; Humans; Liver Fun

2014
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
    BMC cancer, 2011, Jul-26, Volume: 11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxy

2011

Other Studies

26 other studies available for niacinamide and Venous Thrombosis

ArticleYear
Might Sorafenib combined with radiotherapy be better option for treating hepatocellular carcinoma with portal vein tumour thrombosis?
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms

2018
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
    World journal of surgical oncology, 2013, Aug-02, Volume: 11, Issue:1

    Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; P

2013
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
    Journal of surgical oncology, 2014, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant

2014
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
    BMC gastroenterology, 2014, May-03, Volume: 14

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Kaplan-Meier

2014
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Journal of gastroenterology, 2015, Volume: 50, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat

2015
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Clinical radiology, 2014, Volume: 69, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi

2014
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbid

2015
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
    Zhonghua yi xue za zhi, 2014, Sep-09, Volume: 94, Issue:33

    Topics: Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined

2014
Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Journal of vascular and interventional radiology : JVIR, 2015, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy;

2015
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
    Clinical journal of gastroenterology, 2015, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatic Ve

2015
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; L

2016
[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Embolization,

2015
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
    Medicine, 2016, Volume: 95, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Mo

2016
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi

2016
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    World journal of gastroenterology, 2016, Apr-07, Volume: 22, Issue:13

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherap

2016
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver N

2016
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
    European radiology, 2017, Volume: 27, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Huma

2017
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
    World journal of gastroenterology, 2016, Nov-14, Volume: 22, Issue:42

    Topics: Aged; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembol

2016
Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices;

2008
[Regression of vena cava tumour thrombus in response to sorafenib].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney;

2008
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
    Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Humans; Liver Neoplasms; Male

2011
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc

2010
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:5

    Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherap

2011
Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
    Urologia internationalis, 2012, Volume: 88, Issue:2

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kid

2012
[A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispla

2012
1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.
    British journal of pharmacology, 2007, Volume: 152, Issue:2

    Topics: Animals; Aorta; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Epoprostenol; Fibrinolytic Agents; Hy

2007